Opioid-Induced Constipation Market Top Companies Analysis, Regional Growth Overview and Growth Factors Details And Forecast 2022-2027|Takeda Pharmaceuticals, Bayer, Sanofi

Market Insights:

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives. Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%. North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent. In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc. Market Analysis and Insights: Global Opioid-Induced Constipation Market The global Opioid-Induced Constipation market size is projected to reach US$ 3315 million by 2027, from US$ 2415 million in 2020, at a CAGR of 4.6% during 2021-2027.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)  https://www.qyresearch.com/sample-form/form/3266055/global-opioid-induced-constipation-market

 QY Research offers an encyclopedic study of the global Opioid-Induced Constipation market with holistic insights into vital factors and aspects that impact future market growth. The global Opioid-Induced Constipation market has been analyzed for the forecast period 2022-2028 and historical period 2017-2021. In order to help players to gain comprehensive understanding of the global Opioid-Induced Constipation market and its critical dynamics, the research study provides detailed qualitative and quantitative analysis. Furthermore, readers are offered with complete and thorough research on different regions and segments of the global Opioid-Induced Constipation market. Almost all industry-specific, microeconomic, and macroeconomic factors influencing the global market growth have been analyzed in the report.

With an exhaustive analysis of the competitive landscape, the authors of the Opioid-Induced Constipation market report have made a brilliant attempt to explore key developments, pricing and business tactics, and future plans of leading companies. Besides the Opioid-Induced Constipation market performance of players in terms of revenue and sales, the analysts shed light on their production, areas served, gross margin, and other important factors. In addition, the Opioid-Induced Constipation report helps players to gain an upper hand in the market competition as it deeply analyzes the market positioning, market growth, and product portfolio of their competitors.

Key Players Mentioned in the Global Opioid-Induced Constipation Market Research Report: Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi

Global Opioid-Induced Constipation Market Segmentation by Product: Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others

Global Opioid-Induced Constipation Market Segmentation by Application:  Hospital
Pharmacy
Other

The report is the best compilation of different types of segmental analysis of the global Opioid-Induced Constipation market conducted from different angles. The pragmatic approach taken by analysts to study various market segments and the top-down and bottom-up approaches adopted to forecast their market sizes make Opioid-Induced Constipation research study unique and accurate. For validation and revalidation of market figures and other findings, reliable primary sources such as technology and innovation directors, MDs, VPs, CEOs, and supply-side and demand-side industry experts were consulted. Secondary sources such as Bloomberg, databases, white papers, press releases, and company reports were used to collect market information and data.

This research study can be used by all participants of the global Opioid-Induced Constipation market as it covers every major and minor aspect of the current and future market competition. Even for stakeholders, it can prove highly beneficial, considering the range of studies offered along with detailed analysis of growth strategies that players are expected to adopt in the coming years. New entrants or players looking to make a foray into the global Opioid-Induced Constipation market can gather useful information and effective advice from the report. On the other hand, established companies can use the Opioid-Induced Constipation report to stay updated about current and future market scenarios and plan out their future business moves.

Reasons to Procure this Report: -

(A) The research would help top administration/policymakers/professionals/product advancements/sales managers and stakeholders in this market in the following ways.

(B) The report provides Opioid-Induced Constipation market revenues at the worldwide, regional, and country-level with a complete analysis to 2028 permitting companies to analyze their market share and analyze projections, and find new markets to aim.

(C) The research includes the Opioid-Induced Constipation market split by different types, applications, technologies, and end-uses. This segmentation helps leaders plan their products and finances based on the upcoming development rates of each segment.

(D) Opioid-Induced Constipation market analysis benefits investors by knowing the scope and position of the market giving them information on key drivers, challenges, restraints, and expansion chances of the market and moderate threats.

(E) This report would help to understand competition better with a detailed analysis and key strategies of their competitors and plan their position in the business.

(F) The study helps evaluate Opioid-Induced Constipation business predictions by region, key countries, and top companies' information to channel their investments.

Key Questions Answered in the Report Include:

(1) This report gives all the information about the industry analysis, revenue, and overview, of this market.

(2) What will be the rate of increase in market size and growth rate by the end of the forecast period?

(3) What are the major global Opioid-Induced Constipation market trends influencing the development of the market?

(4) What are the vital results of SWOT analysis of the major players operating in the Opioid-Induced Constipation market?

(5) What are the potential growth opportunities and threats faced by Major competitors in the market?

(6) What are the market opportunities and threats faced by vendors in the Global Opioid-Induced Constipation market?

Request for customization in Report:  https://www.qyresearch.com/customize-request/form/3266055/global-opioid-induced-constipation-market

Table of Content

1 Opioid-Induced Constipation Market Overview
1.1 Opioid-Induced Constipation Product Overview
1.2 Opioid-Induced Constipation Market Segment by Type
1.2.1 Methylnaltrexone Bromide
1.2.2 Lubiprostone
1.2.3 Naloxegol
1.2.4 Others
1.3 Global Opioid-Induced Constipation Market Size by Type
1.3.1 Global Opioid-Induced Constipation Market Size Overview by Type (2016-2027)
1.3.2 Global Opioid-Induced Constipation Historic Market Size Review by Type (2016-2021)

1.3.2.1 Global Opioid-Induced Constipation Sales Breakdown in Volume by Type (2016-2021)

1.3.2.2 Global Opioid-Induced Constipation Sales Breakdown in Value by Type (2016-2021)

1.3.2.3 Global Opioid-Induced Constipation Average Selling Price (ASP) by Type (2016-2021)
1.3.3 Global Opioid-Induced Constipation Forecasted Market Size by Type (2022-2027)

1.3.3.1 Global Opioid-Induced Constipation Sales Breakdown in Volume by Type (2022-2027)

1.3.3.2 Global Opioid-Induced Constipation Sales Breakdown in Value by Type (2022-2027)

1.3.3.3 Global Opioid-Induced Constipation Average Selling Price (ASP) by Type (2022-2027)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
1.4.2 Europe Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
1.4.3 Asia-Pacific Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
1.4.4 Latin America Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
1.4.5 Middle East and Africa Opioid-Induced Constipation Sales Breakdown by Type (2016-2021) 2 Global Opioid-Induced Constipation Market Competition by Company
2.1 Global Top Players by Opioid-Induced Constipation Sales (2016-2021)
2.2 Global Top Players by Opioid-Induced Constipation Revenue (2016-2021)
2.3 Global Top Players Opioid-Induced Constipation Price (2016-2021)
2.4 Global Top Manufacturers Opioid-Induced Constipation Manufacturing Base Distribution, Sales Area, Product Type
2.5 Opioid-Induced Constipation Market Competitive Situation and Trends
2.5.1 Opioid-Induced Constipation Market Concentration Rate (2016-2021)
2.5.2 Global 5 and 10 Largest Manufacturers by Opioid-Induced Constipation Sales and Revenue in 2020
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2020)
2.7 Date of Key Manufacturers Enter into Opioid-Induced Constipation Market
2.8 Key Manufacturers Opioid-Induced Constipation Product Offered
2.9 Mergers & Acquisitions, Expansion 3 Opioid-Induced Constipation Status and Outlook by Region
3.1 Global Opioid-Induced Constipation Market Size and CAGR by Region: 2016 VS 2021 VS 2026
3.2 Global Opioid-Induced Constipation Historic Market Size by Region
3.2.1 Global Opioid-Induced Constipation Sales in Volume by Region (2016-2021)
3.2.2 Global Opioid-Induced Constipation Sales in Value by Region (2016-2021)
3.2.3 Global Opioid-Induced Constipation Sales (Volume & Value) Price and Gross Margin (2016-2021)
3.3 Global Opioid-Induced Constipation Forecasted Market Size by Region
3.3.1 Global Opioid-Induced Constipation Sales in Volume by Region (2022-2027)
3.3.2 Global Opioid-Induced Constipation Sales in Value by Region (2022-2027)
3.3.3 Global Opioid-Induced Constipation Sales (Volume & Value), Price and Gross Margin (2022-2027) 4 Global Opioid-Induced Constipation by Application
4.1 Opioid-Induced Constipation Market Segment by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.1.3 Other
4.2 Global Opioid-Induced Constipation Market Size by Application
4.2.1 Global Opioid-Induced Constipation Market Size Overview by Application (2016-2027)
4.2.2 Global Opioid-Induced Constipation Historic Market Size Review by Application (2016-2021)

4.2.2.1 Global Opioid-Induced Constipation Sales Breakdown in Volume, by Application (2016-2021)

4.2.2.2 Global Opioid-Induced Constipation Sales Breakdown in Value, by Application (2016-2021)

4.2.2.3 Global Opioid-Induced Constipation Average Selling Price (ASP) by Application (2016-2021)
4.2.3 Global Opioid-Induced Constipation Forecasted Market Size by Application (2022-2027)

4.2.3.1 Global Opioid-Induced Constipation Sales Breakdown in Volume, by Application (2022-2027)

4.2.3.2 Global Opioid-Induced Constipation Sales Breakdown in Value, by Application (2022-2027)

4.2.3.3 Global Opioid-Induced Constipation Average Selling Price (ASP) by Application (2022-2027)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Opioid-Induced Constipation Sales Breakdown by Application (2016-2021)
4.3.2 Europe Opioid-Induced Constipation Sales Breakdown by Application (2016-2021)
4.3.3 Asia-Pacific Opioid-Induced Constipation Sales Breakdown by Application (2016-2021)
4.3.4 Latin America Opioid-Induced Constipation Sales Breakdown by Application (2016-2021)
4.3.5 Middle East and Africa Opioid-Induced Constipation Sales Breakdown by Application (2016-2021) 5 North America Opioid-Induced Constipation by Country
5.1 North America Opioid-Induced Constipation Historic Market Size by Country
5.1.1 North America Opioid-Induced Constipation Sales in Volume by Country (2016-2021)
5.1.2 North America Opioid-Induced Constipation Sales in Value by Country (2016-2021)
5.2 North America Opioid-Induced Constipation Forecasted Market Size by Country
5.2.1 North America Opioid-Induced Constipation Sales in Volume by Country (2022-2027)
5.2.2 North America Opioid-Induced Constipation Sales in Value by Country (2022-2027) 6 Europe Opioid-Induced Constipation by Country
6.1 Europe Opioid-Induced Constipation Historic Market Size by Country
6.1.1 Europe Opioid-Induced Constipation Sales in Volume by Country (2016-2021)
6.1.2 Europe Opioid-Induced Constipation Sales in Value by Country (2016-2021)
6.2 Europe Opioid-Induced Constipation Forecasted Market Size by Country
6.2.1 Europe Opioid-Induced Constipation Sales in Volume by Country (2022-2027)
6.2.2 Europe Opioid-Induced Constipation Sales in Value by Country (2022-2027) 7 Asia-Pacific Opioid-Induced Constipation by Region
7.1 Asia-Pacific Opioid-Induced Constipation Historic Market Size by Region
7.1.1 Asia-Pacific Opioid-Induced Constipation Sales in Volume by Region (2016-2021)
7.1.2 Asia-Pacific Opioid-Induced Constipation Sales in Value by Region (2016-2021)
7.2 Asia-Pacific Opioid-Induced Constipation Forecasted Market Size by Region
7.2.1 Asia-Pacific Opioid-Induced Constipation Sales in Volume by Region (2022-2027)
7.2.2 Asia-Pacific Opioid-Induced Constipation Sales in Value by Region (2022-2027) 8 Latin America Opioid-Induced Constipation by Country
8.1 Latin America Opioid-Induced Constipation Historic Market Size by Country
8.1.1 Latin America Opioid-Induced Constipation Sales in Volume by Country (2016-2021)
8.1.2 Latin America Opioid-Induced Constipation Sales in Value by Country (2016-2021)
8.2 Latin America Opioid-Induced Constipation Forecasted Market Size by Country
8.2.1 Latin America Opioid-Induced Constipation Sales in Volume by Country (2022-2027)
8.2.2 Latin America Opioid-Induced Constipation Sales in Value by Country (2022-2027) 9 Middle East and Africa Opioid-Induced Constipation by Country
9.1 Middle East and Africa Opioid-Induced Constipation Historic Market Size by Country
9.1.1 Middle East and Africa Opioid-Induced Constipation Sales in Volume by Country (2016-2021)
9.1.2 Middle East and Africa Opioid-Induced Constipation Sales in Value by Country (2016-2021)
9.2 Middle East and Africa Opioid-Induced Constipation Forecasted Market Size by Country
9.2.1 Middle East and Africa Opioid-Induced Constipation Sales in Volume by Country (2022-2027)
9.2.2 Middle East and Africa Opioid-Induced Constipation Sales in Value by Country (2022-2027) 10 Company Profiles and Key Figures in Opioid-Induced Constipation Business
10.1 Takeda Pharmaceuticals
10.1.1 Takeda Pharmaceuticals Corporation Information
10.1.2 Takeda Pharmaceuticals Introduction and Business Overview
10.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Products Offered
10.1.5 Takeda Pharmaceuticals Recent Development
10.2 Bayer
10.2.1 Bayer Corporation Information
10.2.2 Bayer Introduction and Business Overview
10.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.2.4 Bayer Opioid-Induced Constipation Products Offered
10.2.5 Bayer Recent Development
10.3 Sanofi
10.3.1 Sanofi Corporation Information
10.3.2 Sanofi Introduction and Business Overview
10.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.3.4 Sanofi Opioid-Induced Constipation Products Offered
10.3.5 Sanofi Recent Development
10.4 Mallinckrodt
10.4.1 Mallinckrodt Corporation Information
10.4.2 Mallinckrodt Introduction and Business Overview
10.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.4.4 Mallinckrodt Opioid-Induced Constipation Products Offered
10.4.5 Mallinckrodt Recent Development
10.5 Salix (Bausch Health)
10.5.1 Salix (Bausch Health) Corporation Information
10.5.2 Salix (Bausch Health) Introduction and Business Overview
10.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.5.4 Salix (Bausch Health) Opioid-Induced Constipation Products Offered
10.5.5 Salix (Bausch Health) Recent Development
10.6 AstraZeneca
10.6.1 AstraZeneca Corporation Information
10.6.2 AstraZeneca Introduction and Business Overview
10.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.6.4 AstraZeneca Opioid-Induced Constipation Products Offered
10.6.5 AstraZeneca Recent Development
10.7 Progenics Pharmaceuticals
10.7.1 Progenics Pharmaceuticals Corporation Information
10.7.2 Progenics Pharmaceuticals Introduction and Business Overview
10.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Products Offered
10.7.5 Progenics Pharmaceuticals Recent Development
10.8 Purdue Pharm
10.8.1 Purdue Pharm Corporation Information
10.8.2 Purdue Pharm Introduction and Business Overview
10.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.8.4 Purdue Pharm Opioid-Induced Constipation Products Offered
10.8.5 Purdue Pharm Recent Development
10.9 Nektar Therapeutics
10.9.1 Nektar Therapeutics Corporation Information
10.9.2 Nektar Therapeutics Introduction and Business Overview
10.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.9.4 Nektar Therapeutics Opioid-Induced Constipation Products Offered
10.9.5 Nektar Therapeutics Recent Development
10.10 Daiichi Sankyo
10.10.1 Company Basic Information, Manufacturing Base and Competitors
10.10.2 Opioid-Induced Constipation Product Category, Application and Specification
10.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2016-2021)
10.10.4 Main Business Overview
10.10.5 Daiichi Sankyo Recent Development
10.11 Prestige
10.11.1 Prestige Corporation Information
10.11.2 Prestige Introduction and Business Overview
10.11.3 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.11.4 Prestige Opioid-Induced Constipation Products Offered
10.11.5 Prestige Recent Development
10.12 GSK
10.12.1 GSK Corporation Information
10.12.2 GSK Introduction and Business Overview
10.12.3 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.12.4 GSK Opioid-Induced Constipation Products Offered
10.12.5 GSK Recent Development
10.13 Shionogi
10.13.1 Shionogi Corporation Information
10.13.2 Shionogi Introduction and Business Overview
10.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.13.4 Shionogi Opioid-Induced Constipation Products Offered
10.13.5 Shionogi Recent Development 11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Opioid-Induced Constipation Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Opioid-Induced Constipation Industrial Chain Analysis
11.4 Opioid-Induced Constipation Market Dynamics
11.4.1 Industry Trends
11.4.2 Market Drivers
11.4.3 Market Challenges
11.4.4 Market Restraints 12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Opioid-Induced Constipation Distributors
12.3 Opioid-Induced Constipation Downstream Customers 13 Research Findings and Conclusion 14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach

14.1.1.1 Research Programs/Design

14.1.1.2 Market Size Estimation

14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source

14.1.2.1 Secondary Sources

14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer

Buy Now This Report Click Here: https://www.qyresearch.com/settlement/pre/ed3532fc491a5feed84406487442adec,0,1,global-opioid-induced-constipation-market

Contact US:
QY Research, INC.
17890 Castleton,
Suite 218,
City of industry, CA - 91748
USA: +1 626 295 2442
Email: enquiry@qyresearch.com
Web: http://www.qyresearch.com

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert's resources (included energy automotive chemical medical ICT consumer goods etc."

This release was published on openPR.